請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/98361完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 朱忠瀚 | zh_TW |
| dc.contributor.advisor | Chung-Han Chu | en |
| dc.contributor.author | 高錫彣 | zh_TW |
| dc.contributor.author | Hsi-Wen Kao | en |
| dc.date.accessioned | 2025-08-04T16:10:01Z | - |
| dc.date.available | 2025-08-05 | - |
| dc.date.copyright | 2025-08-04 | - |
| dc.date.issued | 2025 | - |
| dc.date.submitted | 2025-07-31 | - |
| dc.identifier.citation | (1) Ventola, C. L. The antibiotic resistance crisis: part 1: causes and threats. P T. 2015, 40 (4), 277-283.
(2) Klahn, P.; Bronstrup, M. Bifunctional antimicrobial conjugates and hybrid antimicrobials. Nat. Prod. Rep. 2017, 34 (7), 832-885. (3) Piddock, L. J. The crisis of no new antibiotics--what is the way forward? Lancet Infect. Dis. 2012, 12 (3), 249-253. (4) Organization, W. H. Deaths due to AMR Estimated to Reach 10 Million People by 2050, Ministry of Health and WHO Launch National Strategy. 2024. https://www.who.int/indonesia/news/detail/20-08-2024-deaths-due-to-amr-estimated-to-reach-10-million-people-by-2050--ministry-of-health-and-who-launch-national-strategy (accessed 2025 July 12). (5) Brown, E. D.; Wright, G. D. Antibacterial drug discovery in the resistance era. Nature 2016, 529 (7586), 336-343. (6) Tangden, T. Combination antibiotic therapy for multidrug-resistant Gram-negative bacteria. Ups J. Med. Sci. 2014, 119 (2), 149-153. (7) Hooper, D. C.; Jacoby, G. A. Topoisomerase Inhibitors: Fluoroquinolone Mechanisms of Action and Resistance. Cold Spring Harb Perspect Med 2016, 6 (9). (8) Thompson, J.; O'Connor, M.; Mills, J. A.; Dahlberg, A. E. The protein synthesis inhibitors, oxazolidinones and chloramphenicol, cause extensive translational inaccuracy in vivo. J. Mol. Biol. 2002, 322 (2), 273-279. (9) Gordeev, M. F.; Hackbarth, C.; Barbachyn, M. R.; Banitt, L. S.; Gage, J. R.; Luehr, G. W.; Gomez, M.; Trias, J.; Morin, S. E.; Zurenko, G. E.; et al. Novel oxazolidinone-quinolone hybrid antimicrobials. Bioorg. Med. Chem. Lett. 2003, 13 (23), 4213-4216. (10) Prasher, P.; Sharma, M. Hybridization of antimicrobial oxazolidinones with commercial drugs: A fight against the "superbugs". Drug Dev. Res. 2023, 84 (7), 1337-1345. (11) Rayner, B.; Verderosa, A. D.; Ferro, V.; Blaskovich, M. A. T. Siderophore conjugates to combat antibiotic-resistant bacteria. RSC Med. Chem. 2023, 14 (5), 800-822. (12) Soriano, A.; Mensa, J. Mechanism of action of cefiderocol. Rev Esp Quimioter 2022, 35 Suppl 2 (Suppl 2), 16-19. (13) Domingues, S.; Lima, T.; Saavedra, M. J.; Da Silva, G. J. An Overview of Cefiderocol's Therapeutic Potential and Underlying Resistance Mechanisms. Life (Basel) 2023, 13 (7). (14) Lester, W. Rifampin: a semisynthetic derivative of rifamycin--a prototype for the future. Annu. Rev. Microbiol. 1972, 26, 85-102. (15) Campbell, E. A.; Korzheva, N.; Mustaev, A.; Murakami, K.; Nair, S.; Goldfarb, A.; Darst, S. A. Structural mechanism for rifampicin inhibition of bacterial rna polymerase. Cell 2001, 104 (6), 901-912. (16) Bobba, S.; Khader, S. A. Rifampicin drug resistance and host immunity in tuberculosis: more than meets the eye. Trends Immunol. 2023, 44 (9), 712-723. (17) Jin, D. J.; Gross, C. A. Mapping and sequencing of mutations in the Escherichia coli rpoB gene that lead to rifampicin resistance. J. Mol. Biol. 1988, 202 (1), 45-58. (18) Ramaswamy, S.; Musser, J. M. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber Lung Dis. 1998, 79 (1), 3-29. (19) Quan, D. H.; Wang, T.; Martinez, E.; Kim, H. Y.; Sintchenko, V.; Britton, W. J.; Triccas, J. A.; Alffenaar, J. W. Beta-lactam combination treatment overcomes rifampicin resistance in Mycobacterium tuberculosis. Eur. J. Clin. Microbiol. Infect. Dis. 2025, 44 (5), 1279-1284. (20) Ji, Q.; Zhou, B.; Shen, T.; Jiang, T.; Cheng, C.; He, B. The lasso structure, biosynthesis, bioactivities and potential applications of Microcin J25: A novel antibacterial agent with unique mechanisms. Eng. Microbiol. 2023, 3 (3), 100096. (21) Semenova, E.; Yuzenkova, Y.; Peduzzi, J.; Rebuffat, S.; Severinov, K. Structure-activity analysis of microcinJ25: distinct parts of the threaded lasso molecule are responsible for interaction with bacterial RNA polymerase. J. Bacteriol. 2005, 187 (11), 3859-3863. (22) Mahlapuu, M.; Hakansson, J.; Ringstad, L.; Bjorn, C. Antimicrobial Peptides: An Emerging Category of Therapeutic Agents. Front. Cell. Infect. Microbiol. 2016, 6, 194. (23) Idowu, T.; Arthur, G.; Zhanel, G. G.; Schweizer, F. Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model. Eur. J. Med. Chem. 2019, 174, 16-32. (24) Cochrane, S. A.; Li, X.; He, S.; Yu, M.; Wu, M.; Vederas, J. C. Synthesis of Tridecaptin-Antibiotic Conjugates with in Vivo Activity against Gram-Negative Bacteria. J. Med. Chem. 2015, 58 (24), 9779-9785. (25) Dorst, A.; Berg, R.; Gertzen, C. G. W.; Schafle, D.; Zerbe, K.; Gwerder, M.; Schnell, S. D.; Sander, P.; Gohlke, H.; Gademann, K. Semisynthetic Analogs of the Antibiotic Fidaxomicin-Design, Synthesis, and Biological Evaluation. ACS Med Chem Lett. 2020, 11 (12), 2414-2420. (26) Lopez, F. E.; Vincent, P. A.; Zenoff, A. M.; Salomon, R. A.; Farias, R. N. Efficacy of microcin J25 in biomatrices and in a mouse model of Salmonella infection. J. Antimicrob. Chemother. 2007, 59 (4), 676-680. (27) Pavlova, O.; Mukhopadhyay, J.; Sineva, E.; Ebright, R. H.; Severinov, K. Systematic structure-activity analysis of microcin J25. J. Biol. Chem. 2008, 283 (37), 25589-25595. (28) Sutradhar, I.; Zaman, M. H. Evaluation of the effect of temperature on the stability and antimicrobial activity of rifampicin quinone. J. Pharm. Biomed. Anal. 2021, 197, 113941. (29) Umapathi, P.; Ayyappan, J.; Quine, D. Reverse Phase High Pressure Liquid Chromatographic Determination of Rifampin Quinone and Hydrazone in Anti-tuberculosis Fixed-Dose Formulations Containing Sodium Ascorbate as Anti-oxidant. Trop. J. Pharm. Res. 2010, 9 (6), 587-593. (30) Acuña, L.; Hamadat, S.; Corbalán, N. S.; González-Lizárraga, F.; dos-Santos-Pereira, M.; Rocca, J.; Sepúlveda Díaz, J.; Del-Bel, E.; Papy-García, D.; Chehín, R. N.; et al. Rifampicin and Its Derivative Rifampicin Quinone Reduce Microglial Inflammatory Responses and Neurodegeneration Induced In Vitro by α-Synuclein Fibrillary Aggregates. Cells 2019, 8 (8), 776. (31) Kumar, S.; Jena, L. Understanding Rifampicin Resistance in Tuberculosis through a Computational Approach. Genomics Inform 2014, 12 (4), 276-282. (32) Goldstein, B. P. Resistance to rifampicin: a review. J Antibiot (Tokyo) 2014, 67 (9), 625-630. (33) Nair, D. P.; Podgórski, M.; Chatani, S.; Gong, T.; Xi, W.; Fenoli, C. R.; Bowman, C. N. The Thiol-Michael Addition Click Reaction: A Powerful and Widely Used Tool in Materials Chemistry. Chem. Mater. 2013, 26 (1), 724-744. (34) Chen, F. J.; Gao, J. Fast Cysteine Bioconjugation Chemistry. Chem. Eur. J. 2022, 28 (66), e202201843. (35) Zhou, D.; Casavant, J.; Graziani, E. I.; He, H.; Janso, J.; Loganzo, F.; Musto, S.; Tumey, N.; O'Donnell, C. J.; Dushin, R. Novel PIKK inhibitor antibody-drug conjugates: Synthesis and anti-tumor activity. Bioorg. Med. Chem. Lett. 2019, 29 (7), 943-947. (36) Longo, B.; Zanato, C.; Piras, M.; Dall'Angelo, S.; Windhorst, A. D.; Vugts, D. J.; Baldassarre, M.; Zanda, M. Design, Synthesis, Conjugation, and Reactivity of Novel trans,trans-1,5-Cyclooctadiene-Derived Bioorthogonal Linkers. Bioconjugate Chem. 2020, 31 (9), 2201-2210. (37) Pradipta, A. R.; Taichi, M.; Nakase, I.; Saigitbatalova, E.; Kurbangalieva, A.; Kitazume, S.; Taniguchi, N.; Tanaka, K. Uncatalyzed Click Reaction between Phenyl Azides and Acrolein: 4-Formyl-1,2,3-Triazolines as “Clicked” Markers for Visualizations of Extracellular Acrolein Released from Oxidatively Stressed Cells. ACS Sens. 2016, 1 (5), 623-632. (38) Liu, J.; Cui, Z. Fluorescent Labeling of Proteins of Interest in Live Cells: Beyond Fluorescent Proteins. Bioconjugate Chem. 2020, 31 (6), 1587-1595. (39) Saimi, D.; Chen, Z. Chemical tags and beyond: Live-cell protein labeling technologies for modern optical imaging. Smart Mol. 2023, 1 (2), e20230002. (40) Craggs, T. D. Green fluorescent protein: structure, folding and chromophore maturation. Chem. Soc. Rev. 2009, 38 (10), 2865-2875. (41) Tsien, R. Y. The green fluorescent protein. Annu Rev Biochem 1998, 67, 509-544. (42) Heim, R.; Tsien, R. Y. Engineering green fluorescent protein for improved brightness, longer wavelengths and fluorescence resonance energy transfer. Curr. Biol. 1996, 6 (2), 178-182. (43) Zhang, S.; Ai, H. W. A general strategy to red-shift green fluorescent protein-based biosensors. Nat. Chem. Biol. 2020, 16 (12), 1434-1439. (44) Cubitt, A. B.; Woollenweber, L. A.; Heim, R. Understanding structure-function relationships in the Aequorea victoria green fluorescent protein. Methods Cell Biol. 1999, 58, 19-30. (45) Ilagan, R. P.; Rhoades, E.; Gruber, D. F.; Kao, H. T.; Pieribone, V. A.; Regan, L. A new bright green-emitting fluorescent protein--engineered monomeric and dimeric forms. FEBS J. 2010, 277 (8), 1967-1978. (46) Miyawaki, A.; Tsien, R. Y. Monitoring protein conformations and interactions by fluorescence resonance energy transfer between mutants of green fluorescent protein. Methods Enzymol. 2000, 327, 472-500. (47) Los, G. V.; Encell, L. P.; McDougall, M. G.; Hartzell, D. D.; Karassina, N.; Zimprich, C.; Wood, M. G.; Learish, R.; Ohana, R. F.; Urh, M.; et al. HaloTag: a novel protein labeling technology for cell imaging and protein analysis. ACS Chem. Biol. 2008, 3 (6), 373-382. (48) Liu, Y.; Miao, K.; Dunham, N. P.; Liu, H.; Fares, M.; Boal, A. K.; Li, X.; Zhang, X. The Cation-pi Interaction Enables a Halo-Tag Fluorogenic Probe for Fast No-Wash Live Cell Imaging and Gel-Free Protein Quantification. Biochemistry 2017, 56 (11), 1585-1595. (49) Cole, N. B. Site-specific protein labeling with SNAP-tags. Curr Protoc Protein Sci 2013, 73, 30.1.1-30.1.16. (50) Adams, S. R.; Campbell, R. E.; Gross, L. A.; Martin, B. R.; Walkup, G. K.; Yao, Y.; Llopis, J.; Tsien, R. Y. New biarsenical ligands and tetracysteine motifs for protein labeling in vitro and in vivo: synthesis and biological applications. J. Am. Chem. Soc. 2002, 124 (21), 6063-6076. (51) Ng, J. S. W.; Hanspal, M. A.; Matharu, N. S.; Barros, T. P.; Esbjorner, E. K.; Wilson, M. R.; Yerbury, J. J.; Dobson, C. M.; Kumita, J. R. Using Tetracysteine-Tagged TDP-43 with a Biarsenical Dye To Monitor Real-Time Trafficking in a Cell Model of Amyotrophic Lateral Sclerosis. Biochemistry 2019, 58 (39), 4086-4095. (52) Griffin, B. A.; Adams, S. R.; Tsien, R. Y. Specific covalent labeling of recombinant protein molecules inside live cells. Science 1998, 281 (5374), 269-272. (53) Arsic, A.; Hagemann, C.; Stajkovic, N.; Schubert, T.; Nikic-Spiegel, I. Minimal genetically encoded tags for fluorescent protein labeling in living neurons. Nat. Commun. 2022, 13 (1), 314. (54) Giepmans, B. N.; Adams, S. R.; Ellisman, M. H.; Tsien, R. Y. The fluorescent toolbox for assessing protein location and function. Science 2006, 312 (5771), 217-224. (55) Langhorst, M. F.; Genisyuerek, S.; Stuermer, C. A. Accumulation of FlAsH/Lumio Green in active mitochondria can be reversed by beta-mercaptoethanol for specific staining of tetracysteine-tagged proteins. Histochem Cell Biol. 2006, 125 (6), 743-747. (56) Sidhu, S. S. Phage display in pharmaceutical biotechnology. Curr. Opin. Biotechnol. 2000, 11 (6), 610-616. (57) Smith, G. P.; Petrenko, V. A. Phage Display. Chem. Rev. 1997, 97 (2), 391-410. (58) Winter, G.; Griffiths, A. D.; Hawkins, R. E.; Hoogenboom, H. R. Making antibodies by phage display technology. Annu. Rev. Immunol. 1994, 12, 433-455. (59) Ledsgaard, L.; Kilstrup, M.; Karatt-Vellatt, A.; McCafferty, J.; Laustsen, A. H. Basics of Antibody Phage Display Technology. Toxins (Basel). 2018, 10 (6). (60) Danner, S.; Belasco, J. G. T7 phage display: a novel genetic selection system for cloning RNA-binding proteins from cDNA libraries. Proc. Natl. Acad. Sci. U.S.A. 2001, 98 (23), 12954-12959. (61) Chang, C.; Guo, W.; Yu, X.; Guo, C.; Zhou, N.; Guo, X.; Huang, R. L.; Li, Q.; Zhu, Y. Engineered M13 phage as a novel therapeutic bionanomaterial for clinical applications: From tissue regeneration to cancer therapy. Mater. Today Bio. 2023, 20, 100612. (62) Morag, O.; Abramov, G.; Goldbourt, A. Similarities and differences within members of the Ff family of filamentous bacteriophage viruses. J. Phys. Chem. B 2011, 115 (51), 15370-15379. (63) Smith, G. P. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 1985, 228 (4705), 1315-1317. (64) Toseland, C. P. Fluorescent labeling and modification of proteins. J Chem Biol. 2013, 6 (3), 85-95. (65) Bosch, P. J.; Correa, I. R., Jr.; Sonntag, M. H.; Ibach, J.; Brunsveld, L.; Kanger, J. S.; Subramaniam, V. Evaluation of fluorophores to label SNAP-tag fused proteins for multicolor single-molecule tracking microscopy in live cells. Biophys. J. 2014, 107 (4), 803-814. (66) Paige, J. S.; Wu, K. Y.; Jaffrey, S. R. RNA mimics of green fluorescent protein. Science 2011, 333 (6042), 642-646. (67) Deng, H.; Yan, S.; Huang, Y.; Lei, C.; Nie, Z. Design strategies for fluorescent proteins/mimics and their applications in biosensing and bioimaging. TrAC, Trends Anal. Chem. 2020, 122. (68) Williams, D. E.; Dolgopolova, E. A.; Pellechia, P. J.; Palukoshka, A.; Wilson, T. J.; Tan, R.; Maier, J. M.; Greytak, A. B.; Smith, M. D.; Krause, J. A.; et al. Mimic of the green fluorescent protein beta-barrel: photophysics and dynamics of confined chromophores defined by a rigid porous scaffold. J. Am. Chem. Soc. 2015, 137 (6), 2223-2226. (69) Ward, W. W.; Bokman, S. H. Reversible denaturation of Aequorea green-fluorescent protein: physical separation and characterization of the renatured protein. Biochemistry 1982, 21 (19), 4535-4540. | - |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/98361 | - |
| dc.description.abstract | 第一部分: 利福平與Microcin J25共軛物對抑制細菌生長的潛在協同作用
利福平(rifampicin)為現今廣泛使用的一種半合成廣效型抗生素,其抗菌機制藉由結合RNA聚合酶(RNAP)的β次單元來抑制轉錄。隨著現今抗生素的濫用導致人們面臨多重抗藥性的超級細菌威脅,我們因此急迫需要研發新型抗生素來面對難關。其中抗生素共軛物的研發便是解方之一,透過將抗生素與另一個功能性分子,如胜肽、抗體、不同抗生素等,以化學合成方法連接起來進而得到提升膜破壞力、結合專一性、殺菌廣度等促使抗菌能力顯著增強的協同作用。 此次研究我們選定同樣結合RNA聚合酶的胜肽類抗生素Microcin J25 (MccJ25)當作與利福平共軛的標靶藥物並預期具有協同作用,根據晶體結構兩者僅相距20-35 Å。實驗設計上我們分別對利福平做化學炔基修飾及對MccJ25序列上三個不嚴重影響與RNAP結合的位置做個別定點突變並純化出帶有離胺酸的MccJ25突變物。利用五乙二醇及八乙二醇連接基團兩端的羧基與疊氮化物做醯胺偶連反應及點擊化學以合成出三個利福平-MccJ25共軛物。透過最小抑制濃度測試我們發現三個共軛物均可有效抑制革蘭氏陽性菌的金黃色葡萄球菌(Staphylococcus aureus)及枯草桿菌(Bacillus subtilis),而其中一個共軛物可以抑制革蘭氏陰性菌的腸道沙門氏菌(Salmonella enterica)。 雖然我們設計的共軛物有顯著的抗菌能力,然而其抑制程度卻均不及相同濃度的利福平與突變MccJ25的混合物。我們認為缺乏協同效應的原因可能源自連接基團長度或抗生素相對位向無法讓兩者同時正確結合在抑制位點,未來我們的優化方向將嘗試選用更多不同長度的連接基團及對不同MccJ25位置做連接,試圖提升兩者同時結合的可能。 第二部分: 利用Phage display技術篩選可結合GFP螢光基團的環狀胜肽 蛋白質螢光標籤技術為研究蛋白表現、功能、相互作用及細胞內外定位與動態變化的重要工具。現行方法多以將螢光蛋白(如GFP)基因融合於目標蛋白之 N 端或 C 端,或利用可與特定螢光分子共價鍵結的蛋白標籤(如Halo Tag、SNAP-tag)進行標記。本研究旨在建立一套新型螢光標籤系統,藉由合成 GFP 螢光基團衍生物,並運用噬菌體展示技術(phage display)篩選可專一性結合此類螢光分子的小分子胜肽,期望未來可將該胜肽之基因序列融合至目標蛋白,並透過添加 GFP 螢光基團衍生物以達到標記之目的。 該研究初步合成了 GFP 螢光核心結構 HBI 及其三個衍生物(DMHBI、DFHBI、DMABI)並與 M13 噬菌體進行混合螢光測試,結果未觀察到螢光訊號確認了此類螢光基團不會與噬菌體產生非特異性結合。接續將 HBI 與 DMHBI 接上生物素標籤,作為與鍊親合素磁珠結合的探針,以利後續噬菌體展示篩選流程之執行。 | zh_TW |
| dc.description.abstract | Part I. Investigation of Potential Antibacterial Synergistic Effects of Rifampicin–Microcin J25 Conjugates in Inhibiting Bacterial Growth
Rifampicin is a widely used semi-synthetic broad-spectrum antibiotic that inhibits bacterial transcription by binding to the β-subunit of RNA polymerase (RNAP). However, due to the misuse of antibiotics, the rise of multidrug-resistant "superbugs" presents an urgent need for novel antibiotic strategies. Among these, antibiotic conjugates have emerged as promising candidates. By chemically linking antibiotics to other functional molecules, such as peptides, antibodies, or different antibiotics, conjugates can significantly enhance antibacterial efficacy through synergistic effects, including improved membrane disruption, specificity, and broadened bactericidal spectra. In this study, we covalently linked Microcin J25 (MccJ25), a peptide antibiotic also targeting RNAP, to rifampicin, in hope of creating a conjugate with synergistic effect. The two are in close spatial proximity (~20–35 Å) as revealed by the crystal structure. To facilitate conjugation, rifampicin was chemically modified with an alkyne group, while three specific sites within the MccJ25 sequence, previously determined as non-critical for RNAP binding were individually mutated to lysine-containing variants. Using penta- and octa-ethylene glycol linkers containing carboxylic acid at one end and an azide group at the other, three rifampicin–MccJ25 conjugates were synthesized via amide coupling reactions and click chemistry. Minimum inhibitory concentration (MIC) assays demonstrated that all three conjugates effectively inhibited Gram-positive bacteria, including Staphylococcus aureus and Bacillus subtilis. Notably, one conjugate exhibited activity against the Gram-negative bacteria Salmonella enterica. Although our designed conjugates displayed significant antibacterial activities, their efficacy was inferior to that of mixtures of rifampicin and mutant MccJ25 at equivalent concentrations. We propose that the observed lack of synergistic effects could stem from suboptimal linker length or spatial orientation, preventing simultaneous proper binding of both antibiotics to their respective inhibitory sites. Future optimization will explore different linker lengths and alternative conjugation sites on MccJ25 to enhance simultaneous target binding and overall antibacterial synergy. Part II. Identifying Cyclic Peptides That Bind the Pro-Fluorescent GFP Chromophore via Phage Display Fluorescent protein labeling is a vital technique for studying protein expression, function, interactions, and spatial–temporal dynamics both inside and outside of cells. Current strategies commonly involve fusing fluorescent proteins (such as GFP) to the N- or C-terminus of the target protein, or using self-labeling protein tags (such as Halo Tag or SNAP-tag) that covalently bind to specific fluorescent ligands. In this study, we aim to develop a novel fluorescent labeling system by synthesizing GFP chromophore derivatives and screening for small peptide ligands with specific binding affinity to these fluorophores using phage display. The selected peptide sequences may subsequently be genetically fused to target proteins, enabling fluorescent labeling through the addition of corresponding GFP chromophore derivatives. To initiate the system, we synthesized the core GFP chromophore HBI and three derivatives (DMHBI, DFHBI, and DMABI), and examined their fluorescence upon mixing with M13 phage. No fluorescence signal was detected, confirming that these fluorophores do not exhibit nonspecific binding to the phage particles. We then conjugated biotin to HBI and DMHBI, generating biotinylated fluorescent probes for immobilization on streptavidin magnetic beads, thereby enabling downstream phage display selection. | en |
| dc.description.provenance | Submitted by admin ntu (admin@lib.ntu.edu.tw) on 2025-08-04T16:10:01Z No. of bitstreams: 0 | en |
| dc.description.provenance | Made available in DSpace on 2025-08-04T16:10:01Z (GMT). No. of bitstreams: 0 | en |
| dc.description.tableofcontents | 誌謝 I
中文摘要 II Abstract IV Table of Contents VIII List of Figures XII List of Schemes XVI List of Tables XVII Abbreviation XVIII Chapter 1 Part I Introduction 1 1.1 Antibiotic crisis 1 1.2 Antibiotic conjugate 2 1.3 Rifampicin 4 1.4 Microcin J25 7 1.5 Rifampicin-MccJ25 conjugate 10 Chapter 2 Part I Result and Discussion 13 2.1 Conjugation strategy 13 2.1.1 Selection of substitution sites in MccJ25 14 2.1.2 MccJ25 mutation and purification 17 2.1.3 Alkyne-rifampicin 20 2.1.4 Distance measurement and linker design 22 2.2 Evaluating MccJ25 mutants and the Rif-alkyne derivative 24 2.2.1 Inhibition zone assay 24 2.2.2 MIC assay 25 2.3 Conjugation strategy 26 2.3.1 Amide coupling 26 2.3.2 Click reaction 28 2.4 Conjugate Inhibition test 34 2.4.1 Inhibition zone assay of Rif–MccJ25 conjugates 34 2.4.2 MIC assay 42 2.4.3 Resistant mutation test assay 44 2.5 Cysteine conjugate strategy 46 2.6 Cysteine linker design 47 2.6.1 Malemide-azide linker 47 2.6.2 Acryl-azide linker 49 2.7 Michael addition 51 Chapter 3 Part I Conclusion and Futrue work 53 Chapter 4 Part II Introduction 55 4.1 Fluorescent labeling and modification of protein 55 4.2 Genetically encoded fluorescent labels 55 4.3 Protein tags for organic fluorophore 57 4.4 Peptide tags for organic fluorophores 58 4.5 Phage display 59 4.5.1 M13 Phage 60 4.6 Organic fluorophores 61 4.7 Selection of GFP core-binding peptides for fluorescent labeling 63 Chapter 5 Part II Result and Discussion 64 5.1 Synthesis of GFP core derivatives 64 5.2 Phage amplification and quantification 66 5.3 Evaluation of non-specific binding and biotin conjugation strategy 66 Chapter 6 Part II Conclusion and Futrue work 69 Chapter 7 Experimental Section 70 7.1 General information 70 7.2 Biology methods and protocols 72 7.2.1 MccJ25 site directed mutagenesis 72 7.2.2 Procedure for MccJ25 production and purification 73 7.2.3 Inhibition zone assay 75 7.2.4 MIC assay 76 7.2.5 Mutation frequency assay 77 7.2.6 Phage amplification 77 7.2.7 Plaque assay for phage quantification 79 7.3 Spectroscopic methods and analysis 80 7.3.1 Absorbance spectrum measurement 80 7.3.2 Fluorescence emission measurement 80 7.4 Synthetic procedures and characterization of compounds 81 7.4.1 Rif-MccJ25 conjugate 81 7.4.2 GFP core derivative-biotin 108 References 123 Appendix 134 | - |
| dc.language.iso | en | - |
| dc.subject | Microcin J25 (MccJ25) | zh_TW |
| dc.subject | 細胞內成像 | zh_TW |
| dc.subject | 目標專一性結合胜肽 | zh_TW |
| dc.subject | 噬菌體展示技術 | zh_TW |
| dc.subject | 綠色螢光蛋白 | zh_TW |
| dc.subject | 利福平 | zh_TW |
| dc.subject | 藥物共軛物 | zh_TW |
| dc.subject | 協同效應 | zh_TW |
| dc.subject | 多重抗藥性 | zh_TW |
| dc.subject | 螢光標記 | zh_TW |
| dc.subject | Rifampicin | en |
| dc.subject | Drug conjugate | en |
| dc.subject | Synergism effect | en |
| dc.subject | Target-specific binding peptides | en |
| dc.subject | Multidrug resistance (MDR) | en |
| dc.subject | Intracellular imaging | en |
| dc.subject | Fluorescent labeling | en |
| dc.subject | Phage Display | en |
| dc.subject | GFP | en |
| dc.subject | Microcin J25 (MccJ25) | en |
| dc.title | 第一部分:利福平與Microcin J25共軛物對抑制細菌生長的潛在協同作用 第二部分:利用Phage display技術篩選可結合GFP螢光基團的環狀胜肽 | zh_TW |
| dc.title | Part I. Investigation of Potential Antibacterial Synergistic Effects of Rifampicin–Microcin J25 Conjugates Part II. Identifying Cyclic Peptides That Bind the Pro-Fluorescent GFP Chromophore via Phage Display | en |
| dc.type | Thesis | - |
| dc.date.schoolyear | 113-2 | - |
| dc.description.degree | 碩士 | - |
| dc.contributor.oralexamcommittee | 謝俊結;羅禮強 | zh_TW |
| dc.contributor.oralexamcommittee | Jiun-Jie Shie;Lee-Chiang Lo | en |
| dc.subject.keyword | 利福平,Microcin J25 (MccJ25),多重抗藥性,協同效應,藥物共軛物,綠色螢光蛋白,噬菌體展示技術,螢光標記,細胞內成像,目標專一性結合胜肽, | zh_TW |
| dc.subject.keyword | Rifampicin,Microcin J25 (MccJ25),Multidrug resistance (MDR),Synergism effect,Drug conjugate,GFP,Phage Display,Fluorescent labeling,Intracellular imaging,Target-specific binding peptides, | en |
| dc.relation.page | 176 | - |
| dc.identifier.doi | 10.6342/NTU202502890 | - |
| dc.rights.note | 同意授權(限校園內公開) | - |
| dc.date.accepted | 2025-08-01 | - |
| dc.contributor.author-college | 理學院 | - |
| dc.contributor.author-dept | 化學系 | - |
| dc.date.embargo-lift | 2030-07-29 | - |
| 顯示於系所單位: | 化學系 | |
文件中的檔案:
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-113-2.pdf 未授權公開取用 | 10.06 MB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。
